Cervomed Inc (CRVO)

$8.08 -0.40 (-4.72%)
Market Cap 78.46M
Revenue (ttm) 9.74M
Net Income (ttm) -16.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -167.25%
Debt to Equity Ratio 0.00
Volume 22,700
Avg Vol 70,828
Day's Range N/A - N/A
Shares Out 9.25M
Stochastic %K 94%
Beta -0.91
Analysts Strong Sell
Price Target $22.43

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 8:55 PM
$HIVE $CRVO -20% only this month Rottens ….happy Christmas
1 · Reply
Doki0926
Doki0926 Dec. 26 at 8:24 PM
$CRVO what the fuck will happen with this?
1 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 7:46 PM
$CRVO ..rottens
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 7:45 PM
$CRVO another flag for these rottens This company is Full of sh i tty pumpers
0 · Reply
Doki0926
Doki0926 Dec. 26 at 6:28 PM
$CRVO there are no words, absolute tragedy
0 · Reply
Stu_padasso
Stu_padasso Dec. 26 at 5:47 PM
$CRVO absolute fucking garbage convinced now dilution or some other bs is coming down the line
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 5:04 PM
$CRVO 5 k exchanged what do you want to say ? They are agree .. sh ..
0 · Reply
Doki0926
Doki0926 Dec. 26 at 3:36 PM
$CRVO everyone is silent?
0 · Reply
Doki0926
Doki0926 Dec. 26 at 3:36 PM
$CRVO 😂😂😂😂
0 · Reply
Doki0926
Doki0926 Dec. 26 at 3:29 PM
$CRVO WTF
0 · Reply
Latest News on CRVO
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 4, 2025, 5:00 PM EST - 22 days ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Dec 2, 2025, 7:00 AM EST - 24 days ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 2 months ago

CervoMed to Present at the Emerging Growth Conference

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 11:54 AM EDT - 2 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 8, 2025, 7:00 AM EDT - 2 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 2, 2025, 8:00 AM EDT - 3 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 17, 2025, 7:30 AM EDT - 3 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 11:20 AM EDT - 5 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 28, 2025, 7:00 AM EDT - 5 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Jul 8, 2025, 7:00 AM EDT - 6 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 12, 2025, 8:00 AM EDT - 8 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 9 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 25, 2025, 8:00 AM EDT - 9 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 22, 2025, 2:55 AM EDT - 9 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Mar 10, 2025, 4:05 PM EDT - 10 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Jan 29, 2025, 8:00 AM EST - 11 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Messerschmittbf109
Messerschmittbf109 Dec. 26 at 8:55 PM
$HIVE $CRVO -20% only this month Rottens ….happy Christmas
1 · Reply
Doki0926
Doki0926 Dec. 26 at 8:24 PM
$CRVO what the fuck will happen with this?
1 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 7:46 PM
$CRVO ..rottens
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 7:45 PM
$CRVO another flag for these rottens This company is Full of sh i tty pumpers
0 · Reply
Doki0926
Doki0926 Dec. 26 at 6:28 PM
$CRVO there are no words, absolute tragedy
0 · Reply
Stu_padasso
Stu_padasso Dec. 26 at 5:47 PM
$CRVO absolute fucking garbage convinced now dilution or some other bs is coming down the line
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 5:04 PM
$CRVO 5 k exchanged what do you want to say ? They are agree .. sh ..
0 · Reply
Doki0926
Doki0926 Dec. 26 at 3:36 PM
$CRVO everyone is silent?
0 · Reply
Doki0926
Doki0926 Dec. 26 at 3:36 PM
$CRVO 😂😂😂😂
0 · Reply
Doki0926
Doki0926 Dec. 26 at 3:29 PM
$CRVO WTF
0 · Reply
LowCountryHooker
LowCountryHooker Dec. 26 at 2:52 PM
$CRVO
2 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 12:41 PM
$CRVO
0 · Reply
Messerschmittbf109
Messerschmittbf109 Dec. 26 at 9:39 AM
$XTKG $AMCI $CRVO stories of the day
0 · Reply
SGNASlayer
SGNASlayer Dec. 25 at 8:14 AM
$CRVO Investor focus is migrating toward execution sequencing, because growth without leverage now attracts skepticism. Absent traction, patience will erode.
0 · Reply
MV0527
MV0527 Dec. 24 at 1:58 PM
$CRVO The big guys are sitting on a ton of cash.
0 · Reply
MV0527
MV0527 Dec. 24 at 1:56 PM
$CRVO soon
0 · Reply
MV0527
MV0527 Dec. 24 at 1:54 PM
$CRVO
0 · Reply
Doki0926
Doki0926 Dec. 24 at 7:15 AM
$CRVO what can we expect?
1 · Reply
MV0527
MV0527 Dec. 23 at 9:29 PM
$CRVO he's a runner. Run Forest Run
0 · Reply
Dovkav
Dovkav Dec. 23 at 5:12 PM
$CRVO
0 · Reply
MV0527
MV0527 Dec. 23 at 1:14 PM
$CRVO I also don't believe CervoMed has any issues getting financing if needed. Officers wouldn't have bought shares before deluded share value and zi think their strengths are their contacts in Big Pharma and financial options. Signs are there IMO.
0 · Reply
MV0527
MV0527 Dec. 23 at 12:50 PM
$CRVO Cantor Fitzgerald coverage along withHC Wainwright is the primary driver right now. This is so undervalued right now. Based on the positive results this should have popped to the 20's already. I can see Cantor moving it there.
0 · Reply